MGNX vs CRNT Comparison

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Ceragon Networks Ltd is a wireless transport specialist, providing wireless connectivity solutions to markets globally across various industries, including wireless (mobile) network service providers and private networks, enabling them to build new networks and evolve networks towards 4G and 5G services. Its portfolio mainly comprises the IP-20 and IP-50 product series, including integrated multi-technology radio units operating across frequencies from 4 GHz to 86 GHz, as well as single-radio devices used for wireless data transport. Additionally, the company offers turnkey services including: network and radio planning, site survey, installation, network auditing and optimization, and more. Geographically, it derives maximum revenue from India, followed by North America and other regions.